TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

TRex Bio reported positive Phase 1a results for TRB-061, which selectively activated and expanded immunoregulatory Tregs in humans; topline Phase 1b data in atopic dermatitis are expected by mid-2027. The company is advancing TRB-071 through IND-enabling studies and anticipates starting a Phase 1 trial in the first half of 2027. After completing a $133.5 million IPO in October 2026, TRex Bio said its cash runway extends into the second half of 2029.